Cancer Research

AACR

6-Thioguanine Reactivates Epigenetically Silenced Genes in Acute Lymphoblastic Leukemia Cells by Facilitating Proteasome-mediated Degradation of DNMT1

Bifeng Yuan, Jing Zhang, Hongxia Wang, et al.

Updated Version	Access the most recent version of this article at: doi:10.1158/0008-5472.CAN-10-3430

Cited Articles	This article cites 48 articles, 17 of which you can access for free at: http://cancerres.aacrjournals.org/content/71/5/1904.full.html#ref-list-1

E-mail alerts	Sign up to receive free email-alerts related to this article or journal.
Reprints and Subscriptions	To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.
Permissions	To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.

6-Thioguanine Reactivates Epigenetically Silenced Genes in Acute Lymphoblastic Leukemia Cells by Facilitating Proteasome-mediated Degradation of DNMT1

Bifeng Yuan[1], Jing Zhang[1,3], Hongxia Wang[1], Lei Xiong[1], Qian Cai[2], Tina Wang[1], Steven Jacobsen[4], Sriharsa Pradhan[5], and Yinsheng Wang[1,2]

Abstract

Thiopurines including 6-thioguanine (^{S}G), 6-mercaptopurine, and azathioprine are effective anticancer agents with remarkable success in clinical practice, especially in effective treatment of acute lymphoblastic leukemia (ALL). ^{S}G is understood to act as a DNA hypomethylating agent in ALL cells, however, the underlying mechanism leading to global cytosine demethylation remains unclear. Here we report that ^{S}G treatment results in reactivation of epigenetically silenced genes in T leukemia cells. Bisulfite genomic sequencing revealed that ^{S}G treatment universally elicited demethylation in the promoters and/or first exons of the genes that were reactivated. ^{S}G treatment also attenuated the expression of histone lysine-specific demethylase 1 (LSD1), thereby stimulating lysine methylation of the DNA methylase DNMT1 and triggering its degradation via the ubiquitin-proteasomal pathway. Taken together, our findings reveal a previously uncharacterized but vital mechanistic link between ^{S}G treatment and DNA hypomethylation. *Cancer Res; 71(5); 1904–11. ©2011 AACR.*

Introduction

In mammalian cells, methylation of DNA at the C5 of cytosine at CpG dinucleotide is one of the major epigenetic modifications that play important roles in embryonic development, gene regulation, cell differentiation, and genomic imprinting (1, 2). Aberrant methylation within CpG islands in the genome links to genomic instability and leads to the development of many diseases, including cancer (3, 4). Promoter CpG methylation is generally correlated with gene silencing. Previous studies showed that tumor-suppressor genes are silenced owing to methylation of CpG islands in their promoter regions (5, 6). Therefore, promoter cytosine demethylation and the resultant reactivation of silenced genes in cancer cells are feasible approaches to cancer therapy.

DNA methylation in mammalian cells is established and maintained by a family of DNA (cytosine-5)-methyltransferases (DNMT) including DNMT1, DNMT3A, and DNMT3B (7).

DNMT1 functions primarily as a maintenance DNA methyltransferase responsible for methylating hemimethylated CpG sites following DNA replication (8, 9), whereas DNMT3A and DNMT3B exhibit *de novo* methyltransferase activity that establishes DNA methylation patterns (10, 11). Dysregulation in DNMT1 was thought to play a critical role in cellular transformation (12). Along this line, constitutive overexpression of an exogenous mouse DNMT1 results in a significant increase in global DNA methylation that is accompanied by tumorigenic transformation in NIH 3T3 mouse fibroblasts (13). In contrast, DNMT1 knockouts are resistant to colorectal tumorigenesis (14), and knockdown of DNMT1 by either antisense or siRNA results in demethylation and activation of tumor-suppressor genes (15, 16). DNMT1 is upregulated in multiple human cancers (17, 18) and previous studies showed that the regulatory regions of tumor-suppressor genes are hypermethylated in tumors (19). Therefore, DNMT1 has been proposed as a target for anticancer therapy (12). Indeed, preclinical studies using antisense to DNMT1 have shown inhibition of tumor growth both *in vitro* (16) and *in vivo* (20).

Thiopurine drugs, which were first synthesized and investigated by Elion and coworkers (21, 22), are widely used as anticancer and immunosuppressive agents and they have achieved remarkable success in clinical practice, especially for acute lymphoblastic leukemia (ALL) treatment (23–27). ^{S}G is the ultimate active metabolite of all thiopurine prodrugs. It was proposed that ^{S}G exerts its cytotoxic effect via its incorporation into DNA, its subsequent methylation by *S*-adenosyl-L-methionine (*S*-AdoMet) to render S^6-methylthioguanine (S^6mG), which directs the misincorporation of dTMP during DNA replication (27). The resulting S^6mG:T mispair can

Authors' Affiliations: [1]Departments of Chemistry and [2]Environmental Toxicology Graduate Program, University of California, Riverside, California; [3]School of Chemistry and Materials Science, Shaanxi Normal University, Xi'an, P. R. China; [4]Howard Hughes Medical Institute and Department of Molecular, Cell and Developmental Biology, University of California, Los Angeles, California; and [5]New England Biolabs Incorporated, Ipswich, Massachusetts

Corresponding Author: Yinsheng Wang, Department of Chemistry, University of California, Riverside, CA 92521-0403. Phone: 951-827-2700; Fax: 951-827-4713; E-mail: yinsheng.wang@ucr.edu

American Association for **Cancer Research**

trigger the postreplicative mismatch repair (MMR) pathway and futile cycles of repair synthesis may ultimately induce cell death (27). On the other hand, the very low level of conversion of DNA ^SG to S^6mG (<0.02%) in ^SG-treated leukemia cells and the relatively high mutagenic potential of ^SG itself suggest that DNA ^SG may trigger the MMR pathway without being converted to S^6mG (28–30). However, the proposed MMR-related mechanism may not be the only pathway for ^SG to exert its cytotoxic effect during ALL treatment viewing that MMR-deficient ALL cells were also sensitive toward ^SG (31).

Our recent study showed that the treatment of Jurkat-T cells with ^SG could lead to a significant decrease in global cytosine methylation (32). Likewise, the level of cytosine methylation in newly synthesized DNA decreased in MOLT-F4 human malignant lymphoblastic cells and HEK-293 T cells upon treatment with ^SG or 6-MP (33, 34). In addition, treatment of HEK-293T cells with ^SG or 6-MP could elicit a decrease in the enzymatic activity of DNMT1 in the whole-cell lysate and a drop in the level of DNMT1 protein (34). However, the mechanism through which the ^SG induces decreases in DNMT1 protein level and global cytosine methylation remains unclear.

Recent reports revealed that the stability of DNMT1 was regulated by the ubiquitin-proteasome pathway (35), which involves the methylation of lysine residues in DNMT1 through a dynamic interplay between histone lysine methyltransferase Set7 (36, 37) and histone lysine-specific demethylase 1 (LSD1; ref. 37). These studies provided a mechanistic link between DNA and histone methylation systems. Additionally, DNMT1 was found to be rapidly and selectively degraded upon treatment with 5-azacytidine (5-aza-C) or 5-aza-2′-deoxycytidine (5-aza-CdR) through the ubiquitin-proteasomal pathway (35). Therefore, we reason that the ^SG-induced decrease in DNMT1 may occur through a similar mechanism. In this study, we have shown that ^SG could reactivate epigenetically silenced genes in leukemic cells by facilitating proteasome-mediated degradation of DNMT1. In addition, this process involves the downregulation of LSD1, which established the mechanism underlying the ^SG-induced hypomethylation in leukemic cells.

Materials and Methods

Cell culture

Jurkat-T, CEM, HEK-293T, and HL-60 cells (ATCC) were cultured under the ATCC-recommended conditions. Jurkat-T cells were treated with 3 μmol/L ^SG (Sigma) and/or 25 μmol/L MG132 (Enzo Life Sciences International), which is a proteasome inhibitor. The whole-cell extracts were prepared by suspending cells in CelLytic M (Sigma) lysis buffer containing protease inhibitor cocktail (Sigma). Genomic DNA from the cultured cells was isolated by extraction with phenol/chloroform/isoamyl alcohol (25:24:1, v/v) and desalted by ethanol precipitation. Total RNA was extracted from the cultured cells by using RNAeasy mini kit (Qiagen).

HPLC quantification of global cytosine methylation

The level of global cytosine methylation was measured using our previously established method (32). Briefly, genomic DNA (~50 μg) was digested with 2 units of nuclease P1 and 0.008 unit

of calf spleen phosphodiesterase in a buffer containing 30-mmol/L sodium acetate (pH 5.5) and 1-mmol/L zinc acetate at 37°C for 4 hours. To the digestion mixture were then added 12.5 units of alkaline phosphatase and 0.05 unit of snake venom phosphodiesterase in a 50-mmol/L Tris-HCl buffer (pH 8.6). The digestion was continued at 37°C for 3 hours, and the enzymes were removed by chloroform extraction. The amount of nucleosides in the mixture was quantified by UV absorbance measurements. The mixtures were then separated by HPLC on an Agilent 1100 capillary pump (Agilent Technologies) with an Agilent 1100 UV detector monitoring at 260 nm. A 4.6×250-mm Polaris C18 column (5 μm in particle size, Varian Inc.) was used. A solution of 10-mmol/L ammonium formate (pH 4.0, solution A) and a mixture of 10-mmol/L ammonium formate and acetonitrile (70:30, v/v, solution B) were employed as mobile phases. A gradient of 5 minutes 0%–4% B, 45 minutes 4%–30% B, and 5 minutes 30%–100% B was used, and the flow rate was 0.80 mL/min. Under these conditions, we were able to resolve 5-methyl-2′-deoxycytidine (5-mdC) from other nucleosides. The global cytosine methylation in cells was quantified based on the peak areas of 5-mdC and 2′-deoxycytidine (dC) with the consideration of the extinction coefficients of the 2 nucleosides at 260 nm (5,020 and 7,250 L/mol/cm for 5-mdC and dC, respectively).

Bisulfite genomic sequencing analysis

Genomic DNA was treated with sodium bisulfite by using EZ DNA Methylation Kit. Amplified PCR products for *RPIB9* (Rap2-binding protein 9), *PCDHGA12* (protocadherin-γ subfamily A member 12), *DCC* (deleted in colorectal cancer), and *asparaginase* were subcloned using the pGEM-T cloning system (Promega). PCR primers were listed in Table S1. Approximately 15 colonies for each gene were sequenced using an ABI 3730 DNA Analyzer (Applied Biosystems).

Quantitative real-time RT-PCR

cDNA was synthesized by using iScript cDNA synthesis kit (Bio-Rad Laboratories) according to the manufacturer's recommended procedures. Briefly, 1 μg of total RNA was reverse-transcribed with 1 μL iScript reverse transcriptase and 4 μL 5×iScript reaction mixture in a 20 μL reaction volume. The reaction was carried out at 25°C for 5 minutes and at 42°C for 30 minutes. The reverse transcriptase was then deactivated by heating at 85°C for 5 minutes.

Quantitative real-time qRT-PCR was conducted using iQ SYBR Green Supermix kit (Bio-Rad) on a Bio-Rad iCycler system (Bio-Rad), and the running conditions were at 95°C for 3 minutes and 45 cycles at 95°C for 15 seconds, 56°C for 30 seconds, and 72°C for 45 seconds. The comparative cycle threshold (Ct) method (ΔΔCt) was used for the relative quantification of gene expression (38), and *GAPDH* gene was used as the internal control. The mRNA level of each gene was normalized to that of the internal control. The primers for real-time PCR were list on Table S2.

RNA interference assay, quantitative real-time RT-PCR, and Western blot analysis

LSD1 siRNA (5′-UGAAUUAGCUGAAACACAAUU-3′) and siGENOME Non-Targeting siRNA (D-001210–02-05) were

obtained from Dharmacon. HEK-293T cells were transfected with 50 nmol/L siRNA along with Lipofectamine 2000 (Invitrogen) following the manufacturer's recommended procedures. Briefly, cells were seeded in 6-well plates at 70% confluence ($\sim 3 \times 10^5$ cells per well) and transfected with 100 pmol synthetic duplex siRNAs using Lipofectamine 2000 reagent. Cells were incubated for 48 hours, after which total RNA and cellular extracts were prepared. Quantitative real-time RT-PCR was conducted using the same procedures as described above. Primer sequences used for RT-PCR were shown in Table S2, and *GAPDH* was used as an internal control. Cell extracts were subjected to Western blot analysis; antibodies that specifically recognized human DNMT1 (New England Biolabs), DNMT1-K142me (36), LSD1 (Cell Signaling), β-actin (Abcam) were used at 1:3000, 1:1000, 1:10,000, and 1:10,000 dilutions, respectively. Horseradish peroxidase-conjugated secondary goat anti-rabbit antibody (Abcam) was used at a 1:10,000 dilution.

Results

^{S}G treatment leads to decrease in global cytosine methylation in cultured human cells

Thiopurine drugs have been successfully employed for treating ALL (27) and a number of genes in bone marrow leukocytes from ALL patients and in 2 ALL cell lines (Jurkat-T and NALM-6) were found to be epigenetically silenced (39). Viewing that the mean peak concentration of ^{S}G in plasma of ALL patients was 0.52 ± 0.72 μmol/L after oral ^{S}G administration (60 mg/m^2) and 2.7 ± 1.4 μmol/L after continuous intravenous infusion (20 mg/m^2/h; ref. 40), we treated Jurkat-T cells with 3 μmol/L ^{S}G from 6 to 24 hours and assessed the level of global cytosine methylation by using an HPLC method (Fig. S1 shows a typical HPLC trace for monitoring the global cytosine methylation; ref. 32). It turned out that treatment with 3 μmol/L ^{S}G for 6 and 24 hours led to appreciable decreases in global cytosine methylation in Jurkat-T cells, that is, the percentage of cytosine methylation dropped from $3.74 \pm 0.02\%$ in untreated cells to $3.57 \pm 0.12\%$, $3.52 \pm 0.08\%$, and $3.34 \pm 0.03\%$ in cells treated with 3 μmol/L of ^{S}G for 6, 12, and 24 hours, respectively (Fig. 1A). Similarly, ^{S}G exposure could lead to loss in global cytosine methylation in other human cell lines. In this regard, treatment of HEK-293T, HL-60, and CEM cells with 3 μmol/L of ^{S}G for 24 hours resulted in decreases in cytosine methylation from $3.61 \pm 0.16\%$, $3.63 \pm 0.04\%$ and $4.05 \pm 0.14\%$ to $3.46 \pm 0.03\%$, $3.29 \pm 0.07\%$, and $3.75 \pm 0.11\%$, respectively (Fig. 1B).

^{S}G treatment resulted in the reactivation of genes silenced in ALL cells

Previous large-scale CpG methylation analysis revealed that the promoter regions of 11 genes were aberrantly methylated in primary leukocytes from ALL patients and in cultured ALL cells (39). To determine whether the ^{S}G-induced global cytosine hypomethylation can reactivate the expression of these genes, we examined, by using quantitative real-time RT-PCR, the mRNA levels of these genes in Jurkat-T cells before and after ^{S}G treatment. It turned out that mRNA expression levels


Figure 1. ^{S}G treatment results in decreased global cytosine methylation and increased expression of epigenetically silenced genes in human cells. A, the percentages of global cytosine methylation in genomic DNA isolated from Jurkat-T cells that were either treated with ^{S}G alone or pretreated with MG132 (25 μmol/L) for 2 hours and then treated with ^{S}G (3 μmol/L) for the indicated time periods. B, the percentages of global cytosine methylation in genomic DNA isolated from HEK-293T, HL-60, and CEM cells that were untreated or treated with ^{S}G (3 μmol/L) for the time periods indicated. C, change in mRNA expression in Jurkat-T cells following treatment with ^{S}G for 24 hours (white bar) or 48 hours (black bar). The data represent the means and standard deviations of results from 3 independent drug treatments. The paired t-test was conducted to evaluate the difference between control samples and treated samples in A, and B, (*, $P < 0.05$; **, $P < 0.01$; ***, $P < 0.001$).

of all these genes increased in Jurkat-T cells after ^{S}G treatment (Fig. 1C). For instance, there were more than 4-fold increases in mRNA levels of *DCC, KCNK2, LRP1B, NKX6–1, NOPE, PCDHGA12*, and *RPIB9* genes after treatment with ^{S}G for 48 hours.

Figure 2. Bisulfite genomic sequencing shows that ^SG treatment leads to decreased methylation at CpG sites in the predicted promoter region and/or the first exon of genes. A, *PCDHGA12*; B, *RPIB9*; C, *Asparaginase*; D, *DCC*. Each square represents a single CpG site. The number of rows designates the number of the colonies sequenced. White and black squares represent unmethylated and methylated CpGs, respectively. The percentage of CpG methylation is listed underneath each figure.

^{S}G-induced cytosine demethylation in promoter and/or the first exon of genes silenced in ALL cells

To gain insights into the mechanisms responsible for the reactivation of the silenced genes upon ^SG treatment, we carried out bisulfite genomic sequencing of the first exon of *PCDHGA12* gene, the predicted promoter and the first exon of *RPIB9* gene, and the predicted promoters of the *asparaginase* and *DCC* genes in Jurkat-T cells (Fig. 2). These regions

were chosen because the methylation status of the promoter and the first exon of genes are important for the epigenetic regulation of gene expression (5, 39) and the expression levels of these genes were substantially elevated after ^SG treatment (Fig. 1C). Consistent with the global cytosine methylation and quantitative real-time RT-PCR results, the methylation level in the promoter and/or first exon of these examined genes dropped by 7%–16% upon ^SG treatment, suggesting that ^SG

Figure 3. DNMT1 was degraded upon ^{S}G treatment and the degradation could be blocked by a proteasomal inhibitor. A, Western blot analysis of DNMT1 with whole-cell extracts from Jurkat-T cells treated with ^{S}G (3 μmol/L) alone or pretreated with MG132 (25 μmol/L) for 2 hours and then treated with ^{S}G for the indicated time periods. β-actin was used as a loading control. B, expression of DNMT1 mRNA is not reduced in cells treated with ^{S}G. The mRNA level of DNMT1 in Jurkat-T cells treated with ^{S}G (3 μmol/L) for 24 or 48 hours was analyzed by real-time RT-PCR. The bar diagram shows the fold change in the mRNA level of DNMT1. The results represent the means and standard deviations of data from 3 independent experiments.

could induce the demethylation in the predicted promoter and/or the first exon of genes thereby stimulating the expression of these genes.

^{S}G treatment led to the proteasomal degradation of DNMT1

To further explore the molecular mechanism underlying the ^{S}G-induced cytosine demethylation, we determined the protein levels of DNMT1 in the extracts of cells treated with ^{S}G for various time periods as DNMT1 is the major maintenance cytosine methyltransferase in mammalian cells. Immunoblot analysis of cell extract indeed revealed a time-dependent decrease in DNMT1 level following ^{S}G treatment (Fig. 3A).

To determine whether the drop in DNMT1 level was due to the downregulation of its transcription, we measured the mRNA level of DNMT1 by real-time RT-PCR (Fig. 3B). Upon treatment with 3 μmol/L ^{S}G, the DNMT1 transcript level was similar to that of the control cells (Fig. 3B). Thus, the ^{S}G-induced decrease in DNMT1 protein level was not due to a decline in its mRNA level.

A previous report showed that DNMT1 could be rapidly degraded upon 5-aza-CdR treatment through the ubiquitin-proteasomal pathway (35). We reasoned that the ^{S}G-induced DNMT1 degradation might also occur through the same pathway. If this is the case, the drug-elicited DNMT1 degradation should be rescued by pretreating the cells with a proteasome inhibitor. It turned out that treatment of cells with proteasome inhibitor MG132 indeed restored the percentage

of global cytosine methylation (Fig. 1A) and abolished the ^{S}G-mediated decrease in DNMT1 protein level (Fig. 3A), supporting that the ^{S}G-induced degradation of DNMT1 involved the proteasomal pathway.

^{S}G could induce the downregulation of LSD1 and the increase in lysine methylation in DNMT1

Recent studies revealed that the stability of DNMT1 protein was dynamically regulated by its methylation on lysine residues via histone lysine methyltransferase Set7 (36, 37) and histone LSD1 (37). Thus, we further investigated whether the ^{S}G-mediated degradation of DNMT1 involved the alteration in the protein level of Set7 and/or LSD1. It turned out that the treatment of Jurkat-T cells with ^{S}G led to a decrease in LSD1 at both the mRNA and protein levels (Fig. 4A and C); the ^{S}G-induced downregulation of LSD1 in Jurkat-T cells was not restored by MG132 at either mRNA or protein level (Fig. 4B and D), which pointed to the transcriptional regulation of LSD1. However, there was no apparent alteration in Set7 level in Jurkat-T cells treated with ^{S}G (Fig. S2). In addition, siRNA knockdown of LSD1 in HEK-293T cells (Fig. S3) induced the degradation of DNMT1 as did ^{S}G (Fig. S4 A and B), revealing that ^{S}G may trigger DNMT1 degradation via diminishing the LSD1 expression.

It was reported that K142 was a major site responsible for the regulation of DNMT1 stability (36). Next, we assessed whether ^{S}G treatment could result in the alteration of K142 methylation in DNMT1. Immunoblot results showed that there was no significant change in K142-methylated DNMT1 in Jurkat-T or HEK-293T cells upon treatment with ^{S}G (Fig. S5 and Fig. S4C). However, the total amount of DNMT1 protein decreased markedly upon ^{S}G treatment (Fig. 3A), suggesting that the percentage of K142-methylated DNMT1 increased upon ^{S}G treatment. In addition, the methylated DNMT1 protein was rapidly degraded by the ubiquitin-proteasome pathway, which may account for the lack of accumulation of the methylated DNMT1 upon ^{S}G treatment. In this vein, it was found that the methylated DNMT1 had a much shorter half-life (2–6 hours) than its unmethylated counterpart (12–24 hours; ref. 36). Taken together, our results have shown that ^{S}G could decrease the expression of LSD1, which led to enhanced lysine methylation in DNMT1 and its subsequent degradation via the proteasomal pathway.

Discussion

We investigated the epigenetic effect of ^{S}G and discovered a novel mechanism underlying the ^{S}G-induced global cytosine demethylation in ALL cells. Our results have shown that ^{S}G exerted its epigenetic effect by downregulating the expression of LSD1, thereby enhancing the lysine methylation level in DNMT1 and triggering its degradation via the proteasomal pathway. The diminished DNMT1 expression led to subsequent promoter demethylation and reactivation of epigenetically silenced genes in ALL cells.

Treatment of Jurkat-T cells with ^{S}G resulted in elevated expression of 12 genes, 11 of which were previously shown to be epigenetically silenced in primary ALL cells and 2 ALL cell

Figure 4. LSD1 expression was decreased upon ^{S}G treatment. A, real-time RT-PCR analysis of the expression of LSD1 mRNA in cells treated with ^{S}G for various time periods. B, real-time RT-PCR analysis of the expression of LSD1 mRNA in cells pretreated with MG132 (25 µmol/L) for 2 hours and then treated with ^{S}G (3 µmol/L) for various time periods. The results represent the means and standard deviations of data from 3 independent experiments. C, western blot analysis of LSD1 with whole-cell extracts from Jurkat-T cells treated with ^{S}G (3 µmol/L) for various time periods. D, western blot analysis of LSD1 with whole-cell extracts from Jurkat-T cells pretreated with MG132 (25 µmol/L) for 2 hours and then treated with ^{S}G for various time periods. The histograms shown under (C) and (D) are the LSD1 fold changes, which were obtained by normalizing the band intensity of LSD1 to that of the loading control, β-actin. The results represent the means and standard deviations of data from 3 independent drug treatment and Western blot experiments.

lines (39). Although the explicit roles of these genes in the pathobiology of ALL remain unclear, the epigenetically silenced state of these genes in ALL cells and their reactivation upon ^{S}G treatment suggest that these genes might serve as important molecular targets for ALL treatment and act as biomarkers for monitoring the efficacy of ALL treatment. *ABCB1, RPIB9*, and *PCDHGA12* have functions that may be associated with patient response to ALL chemotherapy (41, 42). *DCC, DLC-1*, and *LRP1B* were identified as tumor-suppressor genes and were aberrantly methylated in cancer cells (43–45). Bisulfite sequencing analysis revealed the drug-induced demethylation in the putative promoter and/or the first exon of *DCC, asparaginase, RPIB9*, and *PCDHGA12* genes, which provided insights into the mechanisms accounting for the elevated mRNA expression of these genes in Jurkat-T cells after ^{S}G treatment.

An interesting observation is that the expression level of the asparaginase gene was increased upon ^{S}G treatment. Different from normal cells, ALL cells are unable to synthesize the nonessential amino acid asparagine (46); thus, the survival of leukemic cells depends on circulating asparagine. This forms the basis of using *E. coli* asparaginase in the clinical treatment of ALL (46, 47), where the enzyme catalyzes the decomposition of L-asparagine to L-aspartic acid and ammonia. In current protocols of ALL treatment, asparaginase, along with other drugs, are often used in the remission-induction phase, whereas methotrexate plus mercaptopurine are frequently used in consolidation treatment (48). Our real-time PCR

results showed a 3-fold increase in *asparaginase* expression upon ^{S}G treatment at 24 hours, which may further deprives the leukemic cells of asparagine and contributes to the killing of residual leukemic cells during the consolidation treatment. Thus, our results underscored a potentially new pathway contributing to the antileukemic effect of ^{S}G. It is important to investigate in the future whether the same finding can be made for ALL patients administered with the thiopurine drug.

It has been recently shown that LSD1 was able to demethylate and stabilize DNMT1 protein from its degradation via the ubiquitin-proteasome pathway (37). By using metabolic labeling method, the authors found that the methylation level of DNMT1 was markedly increased in $Aof2^{1lox/1lox}$ (LSD1-deficient) cells when compared with $Aof2^{2lox/+}$ (LSD1-proficient) cells (37). These results underscored enhanced methylation of DNMT1 protein in the absence of LSD1, suggesting that DNMT1 is susceptible to LSD1-mediated lysine demethylation *in vivo*. The stability of DNMT1 was also regulated by the histone methyltransferase activity of Set7 through the methylation of DNMT1 at K142 (36). In this study, we found that LSD1 was decreased at both the mRNA and protein level, but there was no significant change in Set7 level upon ^{S}G treatment, revealing that the diminished expression of LSD1 may lead to enhanced DNMT1 methylation. The methylated DNMT1 can then be subjected to degradation via the ubiquitin-proteasome pathway. Taken together, this study offers a rational explanation for the demethylation in DNA and reactivation of silenced

genes by [S]G and underscores a new epigenetic effect of [S]G on leukemia treatment.

Disclosure of Potential Conflicts of Interest

The authors declare no conflict of interest.

Authors' Contributions

B. Yuan, J. Zhang, H. Wang, S. Jacobsen, S. Pradhan, and Y. Wang designed research and wrote the article; B. Yuan, J. Zhang, H. Wang, L. Xiong, Q. Cai, and T. Wang performed research.

References

1. Jaenisch R, Bird A. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet 2003;33:245–54.
2. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev 2002;16:6–21.
3. Scarano MI, Strazzullo M, Matarazzo MR, D'Esposito M. DNA methylation 40 years later: its role in human health and disease. J Cell Physiol 2005;204:21–35.
4. Robertson KD. DNA methylation and human disease. Nat Rev Genet 2005;6:597–610.
5. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003;349:2042–54.
6. Costello JF, Fruhwald MC, Smiraglia DJ, Rush LJ, Robertson GP, Gao X, et al. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet 2000;24:132–8.
7. Goll MG, Bestor TH. Eukaryotic cytosine methyltransferases. Annu Rev Biochem 2005;74:481–514.
8. Bestor TH. Activation of mammalian DNA methyltransferase by cleavage of a Zn binding regulatory domain. EMBO J 1992;11:2611–7.
9. Leonhardt H, Page AW, Weier HU, Bestor TH. A targeting sequence directs DNA methyltransferase to sites of DNA replication in mammalian nuclei. Cell 1992;71:865–73.
10. Okano M, Bell DW, Haber DA, Li E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 1999;99:247–57.
11. Okano M, Xie S, Li E. Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases. Nat Genet 1998;19:219–20.
12. Szyf M. DNA methylation properties: consequences for pharmacology. Trends Pharmacol Sci 1994;15:233–8.
13. Wu J, Issa JP, Herman J, Bassett DE Jr., Nelkin BD, Baylin SB. Expression of an exogenous eukaryotic DNA methyltransferase gene induces transformation of NIH 3T3 cells. Proc Natl Acad Sci U S A 1993;90:8891–5.
14. Laird PW, Jackson-Grusby L, Fazeli A, Dickinson SL, Jung WE, Li E, et al. Suppression of intestinal neoplasia by DNA hypomethylation. Cell 1995;81:197–205.
15. Przybylski M, Kozlowska A, Pietkiewicz PP, Lutkowska A, Lianeri M, Jagodzinski PP. Increased CXCR4 expression in AsPC1 pancreatic carcinoma cells with RNA interference-mediated knockdown of DNMT1 and DNMT3B. Biomed Pharmacother 2010;64:254–8.
16. Fournel M, Sapieha P, Beaulieu N, Besterman JM, MacLeod AR. Down-regulation of human DNA-(cytosine-5) methyltransferase induces cell cycle regulators p16(ink4A) and p21(WAF/Cip1) by distinct mechanisms. J Biol Chem 1999;274:24250–6.
17. Issa JP, Vertino PM, Wu J, Sazawal S, Celano P, Nelkin BD, et al. Increased cytosine DNA-methyltransferase activity during colon cancer progression. J Natl Cancer Inst 1993;85:1235–40.
18. Robertson KD, Uzvolgyi E, Liang G, Talmadge C, Sumegi J, Gonzales FA, et al. The human DNA methyltransferases (DNMTs) 1, 3a and 3b: coordinate mRNA expression in normal tissues and overexpression in tumors. Nucleic Acids Res 1999;27:2291–8.
19. Baylin SB, Esteller M, Rountree MR, Bachman KE, Schuebel K, Herman JG. Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum Mol Genet 2001;10:687–92.
20. Ramchandani S, MacLeod AR, Pinard M, von Hofe E, Szyf M. Inhibition of tumorigenesis by a cytosine-DNA, methyltransferase, antisense oligodeoxynucleotide. Proc Natl Acad Sci U S A 1997;94:684–9.
21. Elion GB. Symposium on immunosuppressive drugs. Biochemistry and pharmacology of purine analogues. Fed Proc 1967;26:898–904.
22. Elion GB. The purine path to chemotherapy. Science 1989;244:41–7.
23. Burchenal JH, Murphy ML, Ellison RR, Sykes MP, Tan TC, Leone LA, et al. Clinical evaluation of a new antimetabolite, 6-mercaptopurine, in the treatment of leukemia and allied diseases. Blood 1953;8:965–99.
24. Murray JE, Merrill JP, Harrison JH, Wilson RE, Dammin GJ. Prolonged survival of human-kidney homografts by immunosuppressive drug therapy. N Engl J Med 1963;268:1315–23.
25. Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol 1992;43:329–39.
26. Bertino JR. Improving the curability of acute leukemia: pharmacologic approaches. Semin Hematol 1991;28:9–11.
27. Karran P, Attard N. Thiopurines in current medical practice: molecular mechanisms and contributions to therapy-related cancer. Nat Rev Cancer 2008;8:24–36.
28. Yuan B, O'Connor TR, Wang Y. 6-Thioguanine and S^6-Methylthioguanine are mutagenic in human cells. ACS Chem Biol 2010;5:1021–7.
29. Wang H, Wang Y. LC-MS/MS coupled with stable isotope dilution method for the quantification of 6-thioguanine and S^6-methylthioguanine in genomic DNA of human cancer cells treated with 6-thioguanine. Anal Chem 2010;82:5797–803.
30. Yuan B, Wang Y. Mutagenic and cytotoxic properties of 6-thioguanine, S^6-methylthioguanine, and guanine-S^6-sulfonic acid. J Biol Chem 2008;283:23665–70.
31. Krynetski EY, Krynetskaia NF, Gallo AE, Murti KG, Evans WE. A novel protein complex distinct from mismatch repair binds thioguanylated DNA. Mol Pharmacol 2001;59:367–74.
32. Wang H, Wang Y. 6-Thioguanine perturbs cytosine methylation at the CpG dinucleotide site by DNA methyltransferases in vitro and acts as a DNA demethylating agent in vivo. Biochemistry 2009;48:2290–9.
33. Lambooy LH, Leegwater PA, Van Den Heuvel LP, Bokkerink JP, De Abreu RA. Inhibition of DNA methylation in malignant MOLT F4 lymphoblasts by 6-mercaptopurine. Clin Chem 1998;44:556–9.
34. Hogarth LA, Redfern CP, Teodoridis JM, Hall AG, Anderson H, Case MC, et al. The effect of thiopurine drugs on DNA methylation in relation to TPMT expression. Biochem Pharmacol 2008;76:1024–35.
35. Ghoshal K, Datta J, Majumder S, Bai S, Kutay H, Motiwala T, et al. 5-Aza-deoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the KEN box, bromo-adjacent homology domain, and nuclear localization signal. Mol Cell Biol 2005;25:4727–41.
36. Esteve PO, Chin HG, Benner J, Feehery GR, Samaranayake M, Horwitz GA, et al. Regulation of DNMT1 stability through SET7-

mediated lysine methylation in mammalian cells. Proc Natl Acad Sci U S A 2009;106:5076–81.

37. Wang J, Hevi S, Kurash JK, Lei H, Gay F, Bajko J, et al. The lysine demethylase LSD1 (KDM1) is required for maintenance of global DNA methylation. Nat Genet 2009;41:125–9.

38. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the $2^{-\Delta\Delta CT}$ Method. Methods 2001;25:402–8.

39. Taylor KH, Pena-Hernandez KE, Davis JW, Arthur GL, Duff DJ, Shi H, et al. Large-scale CpG methylation analysis identifies novel candidate genes and reveals methylation hotspots in acute lymphoblastic leukemia. Cancer Res 2007;67:2617–25.

40. Lowe ES, Kitchen BJ, Erdmann G, Stork LC, Bostrom BC, Hutchinson R, et al. Plasma pharmacokinetics and cerebrospinal fluid penetration of thioguanine in children with acute lymphoblastic leukemia: a collaborative Pediatric Oncology Branch, NCI, and Children's Cancer Group study. Cancer Chemother Pharmacol 2001; 47:199–205.

41. McLeod SJ, Shum AJ, Lee RL, Takei F, Gold MR. The Rap GTPases regulate integrin-mediated adhesion, cell spreading, actin polymerization, and Pyk2 tyrosine phosphorylation in B lymphocytes. J Biol Chem 2004;279:12009–19.

42. Baker EK, Johnstone RW, Zalcberg JR, El-Osta A. Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs. Oncogene 2005;24:8061–75.

43. Arakawa H. Netrin-1 and its receptors in tumorigenesis. Nat Rev Cancer 2004;4:978–87.

44. Hankins GR, Sasaki T, Lieu AS, Saulle D, Karimi K, Li JZ, et al. Identification of the deleted in liver cancer 1 gene, DLC1, as a candidate meningioma tumor suppressor. Neurosurgery 2008;63: 771–80; discussion 80–1.

45. Liu CX, Musco S, Lisitsina NM, Yaklichkin SY, Lisitsyn NA. Genomic organization of a new candidate tumor suppressor gene, LRP1B. Genomics 2000;69:271–4.

46. Rizzari C, Zucchetti M, Conter V, Diomede L, Bruno A, Gavazzi L, et al. L-asparagine depletion and L-asparaginase activity in children with acute lymphoblastic leukemia receiving i.m. or i.v. Erwinia C. or E. coli L-asparaginase as first exposure. Ann Oncol 2000;11:189–93.

47. Tsurusawa M, Chin M, Iwai A, Nomura K, Maeba H, Taga T, et al. L-Asparagine depletion levels and L-asparaginase activity in plasma of children with acute lymphoblastic leukemia under asparaginase treatment. Cancer Chemother Pharmacol 2004;53:204–8.

48. Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet 2008;371:1030–43.